SenseTime and Sinopharm Capital have contributed to the oncology surgical device developer’s latest round, which will fund sales, marketing, product and technology improvement.

China-based cancer therapy equipment manufacturer Hygea Medical Technology secured RMB500m ($77m) in series C funding today from investors including image recognition technology producer SenseTime and pharmaceutical firm Sinopharm. Venture capital firm China Growth Capital led the round, which included BioTrack Capital, Chengwei Chuangban, Grand Flight, Junyida Capital, Potential Capital, Sharewin Investment, Suiyong Capital, Yuanhui Capital…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.